Compare AHCO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | IMCR |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2017 | 2016 |
| Metric | AHCO | IMCR |
|---|---|---|
| Price | $10.60 | $30.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $13.25 | ★ $64.70 |
| AVG Volume (30 Days) | ★ 1.4M | 347.6K |
| Earning Date | 05-25-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,244,857,000.00 | $249,428,000.00 |
| Revenue This Year | $9.00 | $14.39 |
| Revenue Next Year | $6.93 | $8.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $7.11 | $23.15 |
| 52 Week High | $11.17 | $40.71 |
| Indicator | AHCO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 39.51 |
| Support Level | $8.73 | N/A |
| Resistance Level | $10.62 | $34.86 |
| Average True Range (ATR) | 0.54 | 1.69 |
| MACD | 0.09 | -0.12 |
| Stochastic Oscillator | 98.48 | 10.94 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.